Serological biochemical markers of surrogate efficacy and safety as a novel approach to drug repositioning

Drug Discovery Today

Volumn 16, Issue 21-22, 2011, Pages 967-975

  Henriksen, Kim ^a   Christiansen, Claus ^a   Karsdal, Morten Asser ^a,b  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; EPITOPE; HEMOGLOBIN A1C; INFLIXIMAB; NEOEPITOPE; OSTEOCALCIN; PIOGLITAZONE; RALOXIFENE; ROFECOXIB; ROSIGLITAZONE; SALCATONIN; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; BREAST CANCER; CLINICAL TRIAL (TOPIC); CROHN DISEASE; DRUG EFFICACY; DRUG INDICATION; DRUG REPOSITIONING; DRUG SAFETY; DRUG SCREENING; DRUG TREATMENT FAILURE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOARTHRITIS; OSTEOPOROSIS; PAIN; PROTEIN PROCESSING; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS;

BIOLOGICAL MARKERS; DRUG DESIGN; DRUG REPOSITIONING; HUMANS; PHARMACEUTICAL PREPARATIONS; SEROLOGIC TESTS; TREATMENT OUTCOME;

EID: 80255132658     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.06.010     Document Type: Review

References (91)

1. M.J. Finley Austin, and L. Babiss Commentary: where and how could biomarkers be used in 2016? AAPS J. 8 2006 E185 E189
2. M.A. Karsdal Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development Biomarkers 14 2009 181 202
3. T.T. Ashburn, and K.B. Thor Drug repositioning: identifying and developing new uses for existing drugs Nat. Rev. Drug Discov. 3 2004 673 683 (Pubitemid 39173508)
4. F. Iorio Discovery of drug mode of action and drug repositioning from transcriptional responses Proc. Natl. Acad. Sci. U.S.A. 107 2010 14621 14626
5. L.A. Tartaglia Complementary new approaches enable repositioning of failed drug candidates Expert Opin. Investig. Drugs 15 2006 1295 1298 (Pubitemid 44615280)
6. E.L. Tobinick The value of drug repositioning in the current pharmaceutical market Drug News Perspect. 22 2009 119 125
7. D.F. Horrobin Modern biomedical research: an internally self-consistent universe with little contact with medical reality? Nat. Rev. Drug Discov. 2 2003 151 154 (Pubitemid 37361647)
8. G. Duyk Attrition and translation Science 302 2003 603 605 (Pubitemid 37310908)
9. H. Hampel Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives Nat. Rev. Drug Discov. 9 2010 560 574
10. Anon. Eli Lilly Halts Development of Semagacestat for Alzheimer's Disease Based on Preliminary Results of Phase III Clinical Trials 2010 Eli Lilly & Co.
11. F.M. Goodsaid, and D.L. Mendrick Translational medicine and the value of biomarker qualification Sci. Transl. Med. 2 2010 47ps44
12. D.F. Ransohoff Proteomics research to discover markers: what can we learn from Netflix? Clin. Chem. 56 2010 172 176
13. A.S. Ptolemy, and N. Rifai What is a biomarker? Research investments and lack of clinical integration necessitate a review of biomarker terminology and validation schema Scand. J. Clin. Lab. Invest. (Suppl.) 242 2010 6 14
14. N.L. Anderson The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum Clin. Chem. 56 2010 177 185
15. D.F. Ransohoff How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design J. Clin. Epidemiol. 60 2007 1205 1219 (Pubitemid 350061148)
16. M.A. Karsdal Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers - are they the cause or the consequence of the disease? Clin. Biochem. 43 2010 793 804
17. K. Henriksen Should biochemical markers of bone turnover be considered standard practice for safety pharmacology? Biomarkers 15 2010 195 204
18. C. Gloeckner Repositioning of an existing drug for the neglected tropical disease onchocerciasis Proc. Natl. Acad. Sci. U.S.A. 107 2010 3424 3429
19. G.A. Petsko When failure should be the option BMC Biol. 8 2010 61
20. C.R. Chong, and D.J. Sullivan Jr. New uses for old drugs Nature 448 2007 645 646 (Pubitemid 47236844)
21. M.J. Keiser Predicting new molecular targets for known drugs Nature 462 2009 175 181
22. M. Campillos Drug target identification using side-effect similarity Science 321 2008 263 266 (Pubitemid 351989100)
23. F. Zhu Update of TTD: therapeutic target database Nucleic Acids Res. 38 2010 D787 D791
24. J.P. Overington How many drug targets are there? Nat. Rev. Drug Discov. 5 2006 993 996 (Pubitemid 44835126)
25. K.C. Frazier The lessons of Vioxx N. Engl. J. Med. 353 2005 1420 1421
26. C.J. Rosen Revisiting the rosiglitazone story: lessons learned N. Engl. J. Med. 363 2010 803 806
27. P.J. Kappelle Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion Cardiovasc. Ther. 2010 Jul 14. [Epub ahead of print]
28. A.C. Gelijns Capturing the unexpected benefits of medical research N. Engl. J. Med. 339 1998 693 698 (Pubitemid 28402097)
29. C.P. Adams, and V.V. Brantner Spending on new drug development1 Health Econ. 19 2010 130 141
30. C.P. Adams, and V.V. Brantner Estimating the cost of new drug development: is it really 802 million dollars? Health Aff. (Millwood) 25 2006 420 428 (Pubitemid 43529550)
31. M.J. Barratt, and D.E. Frail Integration of indications discovery efforts at Pfizer Int. Drug Discov. 2010
32. K.A. O'Connor, and B.L. Roth Finding new tricks for old drugs: an efficient route for public-sector drug discovery Nat. Rev. Drug Discov. 4 2005 1005 1014
33. S.P. Berger Old laws stop drugs being used in valuable new ways Nature 449 2007 972 (Pubitemid 350014579)
34. A.U. Buzdar Phase II evaluation of Ly156758 in metastatic breast cancer Oncology 45 1988 344 345
35. V.C. Jordan, and M. Morrow Tamoxifen, raloxifene, and the prevention of breast cancer Endocr. Rev. 20 1999 253 278 (Pubitemid 30649808)
36. T.D. Lindstrom Disposition and metabolism of a new benzothiophene antiestrogen in rats, dogs and monkeys Xenobiotica 14 1984 841 847 (Pubitemid 15180639)
37. P.D. Delmas Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women N. Engl. J. Med. 337 1997 1641 1647 (Pubitemid 27510100)
38. B. Ettinger Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators JAMA 282 1999 637 645 (Pubitemid 29384151)
39. E.S. Siris Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study J. Bone Miner. Res. 20 2005 1514 1524 (Pubitemid 41243540)
40. S.R. Cummings The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation JAMA 281 1999 2189 2197 (Pubitemid 29275701)
41. V.G. Vogel Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 295 2006 2727 2741
42. E. Barrett-Connor Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N. Engl. J. Med. 355 2006 125 137 (Pubitemid 44050394)
43. D. Tweedie TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets Curr. Alzheimer Res. 4 2007 378 385 (Pubitemid 47421968)
44. D. Schuster Why drugs fail: a study on side effects in new chemical entities Curr. Pharm. Des. 11 2005 3545 3559 (Pubitemid 41300759)
45. Y.Z. Bagger Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis Bone 37 2005 425 430 (Pubitemid 41160502)
46. D.C. Bauer Classification of osteoarthritis biomarkers: a proposed approach Osteoarthritis Cartilage 14 2006 723 727 (Pubitemid 43986366)
47. Anon. Regulatory watch: FDA issues guidance for cardiovascular risk assessment of novel antidiabetic agents Nat. Rev. Drug Discov. 8 2009 99
48. D. Schuppan, and N.H. Afdhal Liver cirrhosis Lancet 371 2008 838 851 (Pubitemid 351323895)
49. H. Hemingway Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease PLoS Med. 7 2010 e1000286
50. K. Saito, and K. Kihara Role of C-reactive protein as a biomarker for renal cell carcinoma Expert Rev. Anticancer Ther. 10 2010 1979 1989
51. A.M. Papini The use of post-translationally modified peptides for detection of biomarkers of immune-mediated diseases J. Pept. Sci. 15 2009 621 628
52. S.B. De Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process Physiol. Rev. 90 2010 465 494
53. L. Cao Rapid release and unusual stability of immunodominant peptide 45-89 from citrullinated myelin basic protein Biochemistry 38 1999 6157 6163
54. R.D. Chapurlat Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study Bone 27 2000 283 286 (Pubitemid 30458823)
55. P. Garnero The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation J. Bone Miner. Res. 18 2003 859 867 (Pubitemid 37294969)
56. P. Qvist Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting Bone 31 2002 57 61 (Pubitemid 34754426)
57. K. Henriksen Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases Osteoporos. Int. 18 2007 681 685 (Pubitemid 46525540)
58. M.A. Karsdal Induction of increased cAMP levels in articular chondrocytes blocks matrix metalloproteinase-mediated cartilage degradation, but not aggrecanase-mediated cartilage degradation Arthritis Rheum. 56 2007 1549 1558 (Pubitemid 46764084)
59. B.C. Sondergaard Calcitonin directly attenuates collagen type II degradation by inhibition of matrix metalloproteinase expression and activity in articular chondrocytes Osteoarthritis Cartilage 14 2006 759 768 (Pubitemid 43986356)
60. B.C. Sondergaard Investigation of the direct effects of salmon calcitonin on human osteoarthritic chondrocytes BMC Musculoskelet. Disord. 11 2010 62
61. B.C. Sondergaard MAPKs are essential upstream signaling pathways in proteolytic cartilage degradation-divergence in pathways leading to aggrecanase and MMP-mediated articular cartilage degradation Osteoarthritis Cartilage 18 2010 279 288
62. K. Henriksen Oral salmon calcitonin-pharmacology in osteoporosis Expert Opin. Biol. Ther. 10 2010 1617 1629
63. M.A. Karsdal Lessons learned from the development of oral calcitonin: the first tablet formulation of a peptide in Phase III clinical trials J. Clin. Pharmacol. 51 2010 460 471
64. M.A. Karsdal Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of salmon calcitonin BMC Clin. Pharmacol. 8 2008 5
65. M.A. Karsdal Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin BMC Clin. Pharmacol. 8 2008 12
66. M.A. Karsdal A pharmacokinetic and pharmacodynamic comparison of synthetic and recombinant oral salmon calcitonin J. Clin. Pharmacol. 49 2009 229 234
67. M.A. Karsdal Influence of food intake on the bioavailability and efficacy of oral calcitonin Br. J. Clin. Pharmacol. 67 2009 413 420
68. L.B. Tanko Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover J. Bone Miner. Res. 19 2004 1531 1538 (Pubitemid 41094356)
69. M.A. Karsdal Should subchondral bone turnover be targeted when treating osteoarthritis? Osteoarthritis Cartilage 16 2008 638 646
70. D.H. Manicourt Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis Arthritis Rheum. 54 2006 3205 3211
71. B.C. Sondergaard The effect of oral calcitonin on cartilage turnover and surface erosion in an ovariectomized rat model Arthritis Rheum. 56 2007 2674 2678
72. J. Couzin Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors Science 306 2004 384 385 (Pubitemid 39372409)
73. C. Meier Use of thiazolidinediones and fracture risk Arch. Intern. Med. 168 2008 820 825 (Pubitemid 351620084)
74. Z. Berberoglu Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women J. Clin. Endocrinol. Metab. 92 2007 3523 3530 (Pubitemid 47435330)
75. J.J. Holst Bone resorption is decreased postprandially by intestinal factors and glucagon-like peptide-2 is a possible candidate Scand. J. Gastroenterol. 42 2007 814 820 (Pubitemid 46897629)
76. J.V. Bonventre Next-generation biomarkers for detecting kidney toxicity Nat. Biotechnol. 28 2010 436 440
77. J.L. Koyner Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury Clin. J. Am. Soc. Nephrol. 5 2010 2154 2165
78. R.E. Ratner Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes Diab. Vasc. Dis. Res. 4 2007 214 221 (Pubitemid 47529211)
79. B.J. Goldstein Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial Curr. Med. Res. Opin. 22 2006 2575 2590 (Pubitemid 46048373)
80. V. Subbiah Of mice and men: divergent risks of teriparatide-induced osteosarcoma Osteoporos. Int. 21 2010 1041 1045
81. J. Dormandy Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive Drug Saf. 32 2009 187 202
82. S. Christgau Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM) Menopause 11 2004 508 518 (Pubitemid 40362149)
83. P. Alexandersen, M.A. Karsdal, P. Qvist, J.Y. Reginster, and C. Christiansen Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-II in postmenopausal women Bone 40 2007 218 222 (Pubitemid 44848419)
84. D.J. Drucker Glucagon-like peptide 2 J. Clin. Endocrinol. Metab. 86 2001 1759 1764 (Pubitemid 32374934)
85. D.B. Henriksen Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD Bone 45 2009 833 842
86. J. Pinkney, T. Fox, and L. Ranganath Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide Ther. Clin. Risk Manag. 6 2010 401 411
87. M.T. Marino Pharmacokinetics and pharmacodynamics of inhaled GLP-1 (MKC253): proof-of-concept studies in healthy normal volunteers and in patients with type 2 diabetes Clin. Pharmacol. Ther. 88 2010 243 250
88. R.E. Steinert, B. Poller, M.C. Castelli, J. Drewe, and C. Beglinger Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects Am. J. Clin. Nutr. 92 2010 810 817
89. K. Strojek, C. Shi, M.A. Carey, and S.J. Jacober Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regimens: a randomized trial Diabetes Obes. Metab 12 2010 916 922
90. S. Kalra, B. Kalra, and N. Agrawal Oral insulin Diabetol. Metab Syndr. 2 2010 66
91. F. Angelico, M. Burattin, C. Alessandri, B.M. Del, and F. Lirussi Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis Cochrane. Database. Syst. Rev. 2007 CD005166